Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tectonic Therapeutic, Inc.AVRO · Entity 5328 | Chief Technology Officer | February 01, 2024 | February 05, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tectonic Therapeutic, Inc.
Report date February 01, 2024 · Filed February 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,104 |
Reported balance
After 2024-02-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-02-01 · Exercise / conversion · Acquired 37,334 · Balance 68,104 |
| Common StockSEC Table I · non-derivative | Direct | 55,872 |
Reported balance
After 2024-02-05 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-02-05 · Tax withholding · Disposed 12,232 · Balance 55,872 F1: On June 10, 2021, the filer was granted 36,344 RSUs. 50% of the shares vested on the second anniversary of the grant date and the remaining 50% vest on the third anniversary of the grant date. This balance includes 18,172 unvested shares. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2027-02-01 | Direct | 111,999 |
Reported balance
After 2024-02-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-01 · Exercise / conversion · Disposed 37,334 · Balance 111,999 F2: The shares subject to the RSU shall vest over 4 years, with 25% vesting annually on each anniversary of the Vesting Commencement Date of February 1, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 10, 2021, the filer was granted 36,344 RSUs. 50% of the shares vested on the second anniversary of the grant date and the remaining 50% vest on the third anniversary of the grant date. This balance includes 18,172 unvested shares.
F2: The shares subject to the RSU shall vest over 4 years, with 25% vesting annually on each anniversary of the Vesting Commencement Date of February 1, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 05, 2024 Filed Feb 5, 2024 20:01 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | Tax withholdingCommon Stock | 12,232 | $1.20 | $14,697.97 |
DisclosureSEC source: 0001127602-24-003481 · form4.xml · nonDerivative · entry 2 Golipour Azadeh · CIK 0001932510 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,872 F1 · balance_after: On June 10, 2021, the filer was granted 36,344 RSUs. 50% of the shares vested on the second anniversary of the grant date and the remaining 50% vest on the third anniversary of the grant date. This balance includes 18,172 unvested shares. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 20:01 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | Exercise / conversionRestricted Stock Unit · Derivative | 37,334 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003481 · form4.xml · derivative · entry 3 Golipour Azadeh · CIK 0001932510 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,999 Underlying: Common Stock · 37,334 shares Expires 2027-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the RSU shall vest over 4 years, with 25% vesting annually on each anniversary of the Vesting Commencement Date of February 1, 2023. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 20:01 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | Exercise / conversionCommon Stock | 37,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003481 · form4.xml · nonDerivative · entry 1 Golipour Azadeh · CIK 0001932510 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,104 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 16:32 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | Tax withholdingCommon Stock | 111 | $1.21 | $133.76 |
DisclosureSEC source: 0001127602-23-018660 · form4.xml · nonDerivative · entry 2 Golipour Azadeh · CIK 0001932510 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,770 F1 · security: Consists of 36,344 RSUs granted on June 10, 2021. 50% of the shares vest on the second anniversary of the grant date and the remaining 50% vest on the third anniversary of the grant date. F2 · kind: Withholding of shares to cover a tax liability due to the vesting of 18,172 RSUs granted on June 10, 2021. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 16:32 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | Tax withholdingCommon Stock | 5,463 | $1.19 | $6,500.97 |
DisclosureSEC source: 0001127602-23-018660 · form4.xml · nonDerivative · entry 1 Golipour Azadeh · CIK 0001932510 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,881 F1 · security: Consists of 36,344 RSUs granted on June 10, 2021. 50% of the shares vest on the second anniversary of the grant date and the remaining 50% vest on the third anniversary of the grant date. F2 · kind: Withholding of shares to cover a tax liability due to the vesting of 18,172 RSUs granted on June 10, 2021. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 17:10 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantRestricted Stock Unit · Derivative | 149,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-004510 · form4.xml · derivative · entry 1 Golipour Azadeh · CIK 0001932510 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,333 Underlying: Common Stock · 149,333 shares Expires 2027-02-01 F1 · derivative.exercise_date: The shares subject to the RSU shall vest over 4 years, with 25% vesting annually on each anniversary of the Vesting Commencement Date of February 1, 2023. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 17:27 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 165,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001127602-22-027231 · form4.xml · derivative · entry 1 Golipour Azadeh · CIK 0001932510 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2032-12-07 F1 · derivative.exercise_date: 50% of the shares shall vest and become exercisable on the first anniversary of the grant date, and the remaining 50% shall vest in equal monthly installments thereafter over a one-year period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.